SCHEMBL2199118

SCHEMBL2199118

CCCCCN[C@@H]([C]=O)CCC(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.44
PLA2G10 O15496 1/20 0.43
EPHX2 P34913 2/20 0.43
PLA2G2C Q5R387 1/20 0.43
GPR84 Q9NQS5 7/20 0.42
PPARG P37231 7/20 0.42
PPARD Q03181 7/20 0.42
PPARA Q07869 7/20 0.42
HDAC11 Q96DB2 5/20 0.42
TSHR P16473 4/20 0.42
PTPN1 P18031 3/20 0.42
ALDH1A1 P00352 2/20 0.42
TLR2 O60603 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
FABP4 P15090 2/20 0.42
FFAR1 O14842 2/20 0.42
FFAR4 Q5NUL3 2/20 0.42
SLC22A6 Q4U2R8 1/20 0.42
SLC22A8 Q8TCC7 1/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6422458 1.00 AKR1B1 (0.44) AKR1B1PLA2G10EPHX2PLA2G2CGPR84
SCHEMBL6312150 0.98 GPR84 (0.46) AKR1B1PLA2G10EPHX2PLA2G2CGPR84
SCHEMBL9655559 0.84 PLA2G10 (0.43) AKR1B1PLA2G10EPHX2PLA2G2CGPR84
SCHEMBL8755003 0.83 GPR84 (0.42) AKR1B1EPHX2GPR84PPARGPPARD
SCHEMBL6312846 0.80 GABRP (0.39) PLA2G2C
SCHEMBL21724244 0.79 PLA2G2C (0.60) AKR1B1PLA2G10PLA2G2CGPR84PPARG
SCHEMBL6322329 0.78 TSHR (0.43) AKR1B1PLA2G2CHDAC11TSHRALDH1A1
SCHEMBL1230703 0.78 NOD1 (0.57) AKR1B1PLA2G10PLA2G2CGPR84PPARG
SCHEMBL438052 0.78 NOD1 (0.57) AKR1B1PLA2G10PLA2G2CGPR84PPARG
SCHEMBL21724681 0.78 PLA2G2C (0.63) PLA2G10PLA2G2CGPR84PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166063-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166063-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP AKR1B1 2163/4885PLA2G10 2842/4885EPHX2 1736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.